Cargando…

Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue

The combination therapy of lumacaftor and ivacaftor (Orkambi(®)) is approved for patients bearing the major cystic fibrosis (CF) mutation: ΔF508. It has been predicted that Orkambi(®) could treat patients with rarer mutations of similar “theratype”; however, a standardized approach confirming effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molinski, Steven V, Ahmadi, Saumel, Ip, Wan, Ouyang, Hong, Villella, Adriana, Miller, John P, Lee, Po‐Shun, Kulleperuma, Kethika, Du, Kai, Di Paola, Michelle, Eckford, Paul DW, Laselva, Onofrio, Huan, Ling Jun, Wellhauser, Leigh, Li, Ellen, Ray, Peter N, Pomès, Régis, Moraes, Theo J, Gonska, Tanja, Ratjen, Felix, Bear, Christine E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582412/ https://www.ncbi.nlm.nih.gov/pubmed/28667089 http://dx.doi.org/10.15252/emmm.201607137

Ejemplares similares

Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
por: Ahmadi, Saumel, et al.
Publicado: (2017)

Functional Rescue of F508del-CFTR Using Small Molecule Correctors
por: Molinski, Steven, et al.
Publicado: (2012)

Anti-Infectives Restore ORKAMBI(®) Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa
por: Laselva, Onofrio, et al.
Publicado: (2020)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Proximity Profiling of the CFTR Interaction Landscape in Response to Orkambi
por: Iazzi, Melissa, et al.
Publicado: (2022)

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators
por: Laselva, Onofrio, et al.
Publicado: (2020)

A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients
por: Jiang, Jia Xin, et al.
Publicado: (2021)

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor
por: Laselva, Onofrio, et al.
Publicado: (2020)

Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA(TM)
por: Laselva, Onofrio, et al.
Publicado: (2021)

Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity
por: Malik, Firhan A., et al.
Publicado: (2015)

High-Throughput Functional Analysis of CFTR and Other Apically Localized Proteins in iPSC-Derived Human Intestinal Organoids
por: Xia, Sunny, et al.
Publicado: (2021)

Attenuation of Phosphorylation-dependent Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Disease-causing Mutations at the Transmission Interface
por: Chin, Stephanie, et al.
Publicado: (2017)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)

Peregrination of the selectivity filter delineates the pore of the human voltage-gated proton channel hH(V)1
por: Morgan, Deri, et al.
Publicado: (2013)

Construction and validation of a homology model of the human voltage-gated proton channel hH(V)1
por: Kulleperuma, Kethika, et al.
Publicado: (2013)

Hydrophobic gasket mutation produces gating pore currents in closed human voltage-gated proton channels
por: Banh, Richard, et al.
Publicado: (2019)

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis
por: Gunawardena, Tarini N. A., et al.
Publicado: (2023)

Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
por: Favia, Maria, et al.
Publicado: (2020)

Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators
por: Laselva, Onofrio, et al.
Publicado: (2018)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

The era of CFTR modulators: improvements made and remaining challenges
por: Cuevas-Ocaña, Sara, et al.
Publicado: (2020)

Cholesterol Interaction Directly Enhances Intrinsic Activity of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
por: Chin, Stephanie, et al.
Publicado: (2019)

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
por: Hollis, Aidan
Publicado: (2019)

Synergy of cAMP and calcium signaling pathways in CFTR regulation
por: Bozoky, Zoltan, et al.
Publicado: (2017)

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein
por: Laselva, Onofrio, et al.
Publicado: (2022)

Molecular dynamics study of Cl(−) permeation through cystic fibrosis transmembrane conductance regulator (CFTR)
por: Zeng, Zhi Wei, et al.
Publicado: (2023)

Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins
por: Molinski, Steven V., et al.
Publicado: (2017)

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics
por: Strug, Lisa J., et al.
Publicado: (2016)

CFTR interactome mapping using the mammalian membrane two‐hybrid high‐throughput screening system
por: Lim, Sang Hyun, et al.
Publicado: (2022)

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator
por: Laselva, Onofrio, et al.
Publicado: (2021)

The short-term effects of ORKAMBI (lumacaftor/ivacaftor) on regional and distal lung structures using functional respiratory imaging
por: Lauwers, Eline, et al.
Publicado: (2021)

Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein
por: Wong, Amy P., et al.
Publicado: (2012)

Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis
por: Quon, Bradley S., et al.
Publicado: (2020)

The CFTR Amplifier Nesolicaftor Rescues TGF-β1 Inhibition of Modulator-Corrected F508del CFTR Function
por: Bengtson, Charles, et al.
Publicado: (2022)

Activation of the omega-3 fatty acid receptor GPR120 mediates anti-inflammatory actions in immortalized hypothalamic neurons
por: Wellhauser, Leigh, et al.
Publicado: (2014)

Molecular Characterization and Antimicrobial Resistance in Neisseria gonorrhoeae, Nunavut Region of Inuit Nunangat, Canada, 2018–2019
por: Singh, Ameeta E., et al.
Publicado: (2021)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Permissive and nonpermissive channel closings in CFTR revealed by a factor graph inference algorithm
por: Moffett, Alexander S., et al.
Publicado: (2022)

The gliadin-CFTR connection: new perspectives for the treatment of celiac disease
por: Maiuri, Luigi, et al.
Publicado: (2019)

Editorial: Real-world experience with CFTR modulator therapy
por: Tümmler, Burkhard, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s19s987sjg0nd2f37elbn0s6il